{
    "2021-02-23": [
        [
            {
                "time": "",
                "original_text": "Beam4.4亿美元收购Guide，基因药物“接力赛”开始，传统药企还有机会吗？",
                "features": {
                    "keywords": [
                        "Beam",
                        "收购",
                        "Guide",
                        "基因药物",
                        "传统药企"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：生物类似药相似性评价正式启动",
                "features": {
                    "keywords": [
                        "医药行业",
                        "生物类似药",
                        "相似性评价"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[异动股]复星医药(02196-HK)涨3.32%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "涨"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[行情]港股药品股造好，中国生物制药涨超12%，四环医药涨超7%，复星医药涨近4%",
                "features": {
                    "keywords": [
                        "港股",
                        "药品股",
                        "中国生物制药",
                        "四环医药",
                        "复星医药",
                        "涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "今日上市ETF | 竞争激烈！追踪创新药指数的ETF又来了，重仓药明康德和恒瑞医药",
                "features": {
                    "keywords": [
                        "ETF",
                        "创新药指数",
                        "药明康德",
                        "恒瑞医药"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智氪|4000亿的“医药茅台”药明康德，凭什么3年涨5倍？",
                "features": {
                    "keywords": [
                        "药明康德",
                        "医药茅台",
                        "涨"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "南向资金高比例持有港股名单",
                "features": {
                    "keywords": [
                        "南向资金",
                        "港股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智通港股通持股分析|2月23日",
                "features": {
                    "keywords": [
                        "港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "上海复星医药（集团）股份有限公司",
                "features": {
                    "keywords": [
                        "复星医药",
                        "集团"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}